HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript.

AuthorsAnne-Cécile Brunac, Anne Laprie, Marie-Pierre Castex, Camille Laurent, François Le Loarer, Marie Karanian, Sophie Le Guellec, Delphine Guillemot, Gaelle Pierron, Anne Gomez-Brouchet
JournalPediatric blood & cancer (Pediatr Blood Cancer) Vol. 67 Issue 5 Pg. e28185 (05 2020) ISSN: 1545-5017 [Electronic] United States
PMID31965718 (Publication Type: Case Reports, Letter)
Chemical References
  • Aminopyridines
  • Carbazoles
  • DNA-Binding Proteins
  • FUS protein, human
  • Lactams
  • Lactams, Macrocyclic
  • Oncogene Proteins, Fusion
  • Piperidines
  • Pyrazoles
  • RNA-Binding Protein FUS
  • TFCP2 protein, human
  • Transcription Factors
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • alectinib
  • lorlatinib
Topics
  • Adolescent
  • Aminopyridines
  • Anaplastic Lymphoma Kinase (antagonists & inhibitors, metabolism)
  • Bone Neoplasms (diagnostic imaging, metabolism, pathology, therapy)
  • Carbazoles (administration & dosage)
  • Chemoradiotherapy
  • DNA-Binding Proteins (metabolism)
  • Female
  • Humans
  • Lactams
  • Lactams, Macrocyclic (administration & dosage)
  • Oncogene Proteins, Fusion (metabolism)
  • Piperidines (administration & dosage)
  • Pyrazoles
  • RNA-Binding Protein FUS (metabolism)
  • Rhabdomyosarcoma (diagnostic imaging, metabolism, pathology, therapy)
  • Transcription Factors (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: